Clay Siegall And His Relentless Fight Against Cancer

There are many cancer research companies out there, but none of them can match the achievements of Seattle Genetics in the battle against cancer. Clay Siegall is the force behind the company, and he serves as its President, CEO, and the Chairman of the Board. Clay has been in charge of Seattle Genetics since 2002. The renowned scientist is described by those close to him as a passionate professional who spends most of his time trying to improve the lives of cancer patients.

Siegall specializes in cancer research and medical studies. According to his admirable resume, Clay holds a Ph.D. in Genetics from George Washington University. He also attended the University of Maryland where he graduated with a Bachelor’s degree in Zoology. Siegall has close to 20 years of experience in research and cancer drug development. To anyone reading about Clay for the first time, his knowledge and experience may seem insignificant until one looks at his career journey. Siegall started his career in 1988 at the National Cancer Institute. He worked for the institution until 1991 when he joined experts at Bristol-Myers Squibb Pharmaceutical Research Institute. Here, he served for only six years after which he founded Seattle Genetics in 1998.

Siegall serves on the Board governing Alder BioPharmaceuticals and Mirna Therapeutics. He recently joined the management team at Ultragenyx, a pharmaceutical company that works with patients and medical professionals to address rare diseases. His company, Seattle Genetics, has grown from a small entity into a global leader, and it mainly focuses on cancer research and drug development. The company introduced the ADC technology and developed the first antibody-drug conjugates, ADCETRIS, which was approved by FDA in 2011. ADCETRIS became successful and is sold in more 60 countries around the world.

Siegall is still striving to ensure continuous improvements of the ADC technology for better cancer treatment options. He participates in numerous seminars and accentuates on the need for prioritization of modern cancer therapies. His knowledge and experience in cancer treatment are amazing, and it places Seattle Genetics among the leading firms that fight cancer using advanced technology.